Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0006024
UniProt IDQ15653
Primary gene name(s)NFKBIB
Synonym gene name(s)IKBB, TRIP9
Protein nameNF-kappa-B inhibitor beta
Protein functionInhibits NF-kappa-B by complexing with and trapping it in the cytoplasm. However, the unphosphorylated form resynthesized after cell stimulation is able to bind NF-kappa-B allowing its transport to the nucleus and protecting it to further NFKBIA-dependent inactivation. Association with inhibitor kappa B-interacting NKIRAS1 and NKIRAS2 prevent its phosphorylation rendering it more resistant to degradation, explaining its slower degradation.
Subcellular locationCytoplasm {ECO:0000250}. Nucleus {ECO:0000250}.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: Q15653
Gene Ontology
(Biological Process)
Complete annatation
cellular response to lipopolysaccharide [GO:0071222];
positive regulation of NF-kappaB transcription factor activity [GO:0051092];
signal transduction [GO:0007165];
transcription, DNA-templated [GO:0006351]
Gene Ontology
(Molecular Function)
Complete annatation
signal transducer activity [GO:0004871];
transcription coactivator activity [GO:0003713]
Gene Ontology
(Cellular Component)
Complete annatation
cytosol [GO:0005829];
nucleus [GO:0005634]
Protein-protein interaction110860
Phylogenetic treeQ15653
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
      unknown
Brass et al., Science, 2008
      unknown
Smith et al., J. Immunol, 2010
      unknown
Interferon-stimulated
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model


DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD31.652019107608919.10905628703773e-077.1246339573551e-06
AZA vs. DISU0.3643882426654080.1547772519443160.736295207806145
AZA vs. IL7-0.1472033325888570.4528285737622330.999311006273513
AZA vs. SAHA-0.2290625974964220.3538959281088810.724026495699412
DISU vs. CD3-1.299852119239410.0004276470878267210.00199824928763174
DISU vs. IL7-0.5216291482520170.04056641731247460.265886409124154
DISU vs. SAHA-0.5905539869711890.04567768812263660.265487249400793
DMSO vs. AZA-0.08049470463158170.6560106745241981
DMSO vs. CD3-1.740441487453951.2593817655393e-071.08912665314866e-06
DMSO vs. DISU-0.4458004321552380.07768930241659160.520072575117221
DMSO vs. IL7-0.05979618241889810.7505442862838520.951609350280672
DMSO vs. SAHA-0.1545617990947190.517327489254120.822309646023549
HIV vs. Mock in Activation0.2539738034386740.6851206184399750.999983755607037
HIV vs. Mock in Latency-0.06870507011866660.6844707124019090.999834320637052
IL7 vs. CD3-1.794784794724316.14002596543983e-087.90338269659049e-07
SAHA vs. CD3-1.904118323453931.95707520078692e-071.899106456913e-06
SAHA vs. IL7-0.08343186100560770.7353942712483130.879648725979771
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) unknown
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.542061 0.00438837
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
0.899 0.966 0.917 0.916 1.009
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

not found

Protein Secondary Structure       (annotations from PDB)      top

not found

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Vpr induces phosphorylation of 23453579
Tat inhibited by 8615004
8709193
Vpr upregulates 20801175
Tat upregulates 25613138
Tat degrades 10480634
10580107
10799874
11511100
Envelope surface glycoprotein gp120 upregulates 15103018

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa04062 Chemokine signaling pathway - Homo sapiens (human)
hsa04621 NOD-like receptor signaling pathway - Homo sapiens (human)
hsa04622 RIG-I-like receptor signaling pathway - Homo sapiens (human)
hsa04623 Cytosolic DNA-sensing pathway - Homo sapiens (human)
hsa04658 Th1 and Th2 cell differentiation - Homo sapiens (human)
hsa04659 Th17 cell differentiation - Homo sapiens (human)
hsa04660 T cell receptor signaling pathway - Homo sapiens (human)
hsa04662 B cell receptor signaling pathway - Homo sapiens (human)
hsa04722 Neurotrophin signaling pathway - Homo sapiens (human)
hsa04920 Adipocytokine signaling pathway - Homo sapiens (human)
hsa05131 Shigellosis - Homo sapiens (human)
hsa05140 Leishmaniasis - Homo sapiens (human)
hsa05145 Toxoplasmosis - Homo sapiens (human)
hsa05162 Measles - Homo sapiens (human)
hsa05164 Influenza A - Homo sapiens (human)
hsa05168 Herpes simplex infection - Homo sapiens (human)
hsa05169 Epstein-Barr virus infection - Homo sapiens (human)
Menu